The lessons of Vioxx—drug safety and sales
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In May, the Government Reform Committee of the U.S. House of Representatives held a hearing that explored how drugs with serious safety issues can remain so popular for so long. Representative Henry Waxman describes how what was learned illuminated the practices that pharmaceutical manufacturers use to promote their products to physicians.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was not until four years of long-term clinical studies that it became evident that the risk of heart attack and stroke was actually two-fold higher with Vioxx compared to the control group [3].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [3]
Citations
Cites
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Dai, C., Stafford, R. S., & Alexander, G. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.171 · Cited by 119
Cited by
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
THE POLITICS OF PUBLIC HEALTH POLICY
Oliver, T. R. (2006) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.25.101802.123126 · Cited by 338
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., & Grann, V. R. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk028 · Cited by 279
Cardiovascular disease models: A game changing paradigm in drug discovery and screening
Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223
Lynch, J. R., Cunningham, M. R. A., Warme, W. J., Schaad, D. C., Wolf, F. M., & Leopold, S. S. (2007) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200705000-00013 · Cited by 173
Archie Cochrane and His Vision for Evidence-Based Medicine
Shah, H. M., & Chung, K. C. (2009) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e3181b03928 · Cited by 145
Human-Derived Organ-on-a-Chip for Personalized Drug Development
Jodat, Y. A., Kang, M., Kiaee, K., Kim, G. J., Martinez, A. F. H., Rosenkranz, A., Bae, H., & Shin, S. R. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190308150055 · Cited by 136
Mintzes, B. J., Lexchin, J., Sutherland, J. M., Beaulieu, M., Wilkes, M. S., Durrieu, G., & Reynolds, E. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2411-7 · Cited by 117
Differential diagnosis of reactive gastropathy
Genta, R. M. (2005) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2006.04.001 · Cited by 101
Pharmaceutical Controversies and the Performative Value of Uncertainty
McGoey, L. (2009) · Science as Culture · doi:10.1080/09505430902885474 · Cited by 102
Scott, P. A., Kingsley, G. H., Smith, C. M., Choy, E., & Scott, D. L. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068650 · Cited by 104
Use of Ezetimibe in the United States and Canada
Jackevicius, C. A., Tu, J. V., Ross, J. S., Ko, D. T., & Krumholz, H. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0801461 · Cited by 95
Ye, F. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i2.126 · Cited by 91
Grande, D. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1016-7 · Cited by 94
Orthopaedics and the Physician Payments Sunshine Act
Iyer, S., Derman, P. B., & Sandhu, H. S. (2016) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.o.00343 · Cited by 79
Cairns, J. A. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70732-8 · Cited by 93
Hershman, D. L., Buono, D. L., Malin, J. L., McBride, R. B., Tsai, W. Y., & Neugut, A. I. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp387 · Cited by 74
Brownstein, J. S., Sordo, M., Kohane, I. S., & Mandl, K. D. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000840 · Cited by 69
A secure distributed logistic regression protocol for the detection of rare adverse drug events
Emam, K. E., Samet, S., Arbuckle, L., Tamblyn, R. M., Earle, C. C., & Kantarcıoğlu, M. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000735 · Cited by 67
Medicines Information and the Regulation of the Promotion of Pharmaceuticals
Alves, T. L., Lexchin, J., & Mintzes, B. J. (2018) · Science and Engineering Ethics · doi:10.1007/s11948-018-0041-5 · Cited by 63
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Rotenstein, L. S., Ran, N. A., Shivers, J. P., Yarchoan, M. M., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.138 · Cited by 61
Psoriasis Is Not a Useful Independent Risk Factor for Cardiovascular Disease
Stern, R. S. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.446 · Cited by 60
Williams, S. A., Murthy, A. C., DeLisle, R. K., Hyde, C., Malarstig, A., Ostroff, R., Weiss, S. J., Segal, M. R., & Ganz, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028213 · Cited by 57
Mapping conflict of interests: scoping review
Chimonas, S., Mamoor, M., Zimbalist, S. A., Barrow, B., Bach, P. B., & Korenstein, D. (2021) · BMJ · doi:10.1136/bmj-2021-066576 · Cited by 54
Promoting More Conservative Prescribing
Schiff, G. D., & Galanter, W. (2009) · JAMA · doi:10.1001/jama.2009.195 · Cited by 49
Vulnerability of Health to Market Forces
Brezis, M., & Wiist, W. H. (2011) · Medical Care · doi:10.1097/mlr.0b013e31820ab638 · Cited by 57
Nanotechnology-Assisted Microfluidic Systems: From Bench to Bedside
Rabiee, N., Ahmadi, S., Fatahi, Y., Rabiee, M., Bagherzadeh, M., Dinarvand, R., Bagheri, B., Zarrintaj, P., Saeb, M. R., & Webster, T. J. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0353 · Cited by 49
Brezis, M. (2008) · PubMed · Cited by 39
Bamidele, O. P., Duodu, K. G., & Emmambux, M. N. (2018) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2018.03.008 · Cited by 41
Ziemer, M., Wiesend, C. L., Vetter, R., Weiss, J. M., Blaschke, S., Norgauer, J., & Mockenhaupt, M. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.711 · Cited by 38
Palladium‐Catalyzed Cross‐Coupling of Alkenyl Carboxylates
Becica, J., Heath, O. R. J., Zheng, C. H. M., & Leitch, D. C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006586 · Cited by 36
Inflammatory Disorders of the Stomach
Lash, R. H., Lauwers, G. Y., Odze, R. D., & Genta, R. M. (2009) · Elsevier eBooks · doi:10.1016/b978-141604059-0.50015-1 · Cited by 32
Illicit Internet availability of drugs subject to recall and patient safety consequences
Mackey, T. K., Aung, P., & Liang, B. A. (2015) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-015-0154-8 · Cited by 27
Cyclooxygenase-2 inhibitors: what went wrong?
James, M. J., & Cleland, L. G. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000214565.67439.83 · Cited by 21
Kappe, E., & Stremersch, S. (2016) · Marketing Science · doi:10.1287/mksc.2015.0971 · Cited by 25
Villamizar–Mogotocoro, A., Rojas, A. F. L., & Urbina, J. M. (2020) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x17666200220130735 · Cited by 18
Industry payments to pathologists in the USA between 2013 and 2021
Murayama, A., & Hirota, S. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-208901 · Cited by 17
Endoscopic treatment of reflux: management pros and cons
Lorenzo, A. J., & Khoury, A. E. (2006) · Current Opinion in Urology · doi:10.1097/01.mou.0000232054.12461.5f · Cited by 17
It's Time to Shine the Light on Direct-to-Consumer Advertising
Mackey, T. K., & Liang, B. A. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1711 · Cited by 16
Leibovici, L., & Falagas, M. E. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.01.002 · Cited by 14
Phenotyping drug polypharmacology via eicosanoid profiling of blood
Song, J., Liu, X., Rao, T. S., Chang, L., Meehan, M. J., Blevitt, J. M., Wu, J., Dorrestein, P. C., & Milla, M. E. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m058677 · Cited by 13
Brown, S. D., Daly, J. C., Kalish, L. A., & McDaniel, S. (2006) · Radiology · doi:10.1148/radiol.2393050744 · Cited by 13
Beyond Blood Pressure: Subtle Effects of Drug Classes
O’Rourke, M. F. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000189321.13314.f7 · Cited by 11
Ross, J. S., & Krumholz, H. M. (2018) · BMJ · doi:10.1136/bmj.k242 · Cited by 10
Examining Metaphors in Biopolitical Discourse
Coleman, C., & Ritchie, L. D. (2011) · Lodz Papers in Pragmatics · doi:10.2478/v10016-011-0003-8 · Cited by 9
Louw, J. A. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000245532.12648.aa · Cited by 9
Frazier, K. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmc055294 · Cited by 9
[Rational use of medicines: the pivotal role of the pharmacist].
Bergsten‐Mendes, G. (2008) · PubMed · doi:10.1590/s1413-81232008000700003 · Cited by 8
Innovative therapeutic strategies to overcome radioresistance in breast cancer
Arnold, C. R., Mangesius, J., Portnaia, I., Ganswindt, U., & Wolff, H. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379986 · Cited by 8
Palladium‐Catalyzed Cross‐Coupling of Alkenyl Carboxylates
Becica, J., Heath, O. R. J., Zheng, C. H. M., & Leitch, D. C. (2020) · Angewandte Chemie · doi:10.1002/ange.202006586 · Cited by 8
Why America Needs a Strong FDA
Markel, H. (2005) · JAMA · doi:10.1001/jama.294.19.2489 · Cited by 8
Tamblyn, R. M., Girard, N., Dixon, W. G., Haas, J. S., Bates, D. W., Sheppard, T., Eguale, T., Buckeridge, D. L., Abrahamowicz, M., & Forster, A. J. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.03.033 · Cited by 10
Recent international initiatives of drug safety management
Choi, N., Lee, J., & Park, B. (2012) · Journal of Korean Medical Association · doi:10.5124/jkma.2012.55.9.819 · Cited by 7
Regulatory Components for Treating Persistent Pain in Long-term Care
Planton, J., & Edlund, B. J. (2010) · Journal of Gerontological Nursing · doi:10.3928/00989134-20100202-02 · Cited by 6
A case study of Vioxx using STAMP
Couturier, M. (2010) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 6
Ethical Issues in Pediatric Anesthesiology
Waisel, D. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-42974-0.00005-7 · Cited by 8
Regulatory considerations for new drugs and devices
Chen, K., Lim, T. P., Yuen, J. S. P., Ho, H. S. S., & Murphy, D. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-90186-4.00060-2 · Cited by 4
Steele, F. R. (2005) · Cell · doi:10.1016/j.cell.2005.11.033 · Cited by 4
Introductory Chapter: Pharmacovigilance and Public Health Safety
Herdeiro, M. T., Silva, T. M., Ribeiro‐Vaz, I., Gomes, E. R., Figueiras, A., & Roque, F. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95293 · Cited by 3
MacDougall, C., Udkow, T., Guglielmo, B. J., Vittinghoff, E., & Martin, J. N. (2010) · Journal of the American Pharmacists Association · doi:10.1331/japha.2010.09086 · Cited by 3
Slotki, I. N., & Skorecki, K. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10014-4 · Cited by 3
Unusual Causes of Ischaemic Stroke and Transient Ischaemic Attack
Warlow, C., van Gijn, J., Dennis, M. S., Wardlaw, J. M., Bamford, J., Hankey, G. J., Sandercock, P. A., Rinkel, G. J. E., Langhorne, P., Sudlow, C. L. M., et al. (2008) · Wiley eBooks · doi:10.1002/9780470696361.ch7 · Cited by 3
Quinn, T. (2017) · Annals of Internal Medicine · doi:10.7326/acpjc-2017-167-6-030 · Cited by 3
Allal‐Chérif, O., Gallego-Nicholls, J. F., Carrilero-Castillo, A., & Garcia, F. J. S. (2024) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2024.123906 · Cited by 3
Who's afraid of biomedicine? Insights, fears, risks and opportunities
Sargent, M. (2005) · Interdisciplinary Science Reviews · doi:10.1179/030801805x42117 · Cited by 2
Cardiovascular Safety in Drug Development: A Role for Endothelial Function Tests
Ruiz-García, J., & Alegría‐Barrero, E. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416639719 · Cited by 2
Organic Synthesis in Drug Discovery and Development
Šunjić, V., & Parnham, M. J. (2011) · Springer eBooks · doi:10.1007/978-3-0348-0125-6_1 · Cited by 4
Hsieh, C., Chang, P.-Y., Lu, P., & Huang, W.-F. (2011) · Journal of Pharmaceutical Health Services Research · doi:10.1111/j.1759-8893.2011.00056.x · Cited by 1
Policy for drug safety and its impact on the patient safety
Park, B. (2012) · Journal of Korean Medical Association · doi:10.5124/jkma.2012.55.9.816 · Cited by 1
Ethics of Research in Patients with Pain
van der Velden, M. G., & Waisel, D. B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-08340-9.00081-5 · Cited by 1
Las furan-2[5H]-onas (Da,B-butenolidas), su preparación e importancia biológica
Rojas, A. F. L., & Urbina, J. M. (2015) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 1
Roberts, J., & Mitchell, L. M. (2019) · Éditions de l'Université de Sherbrooke eBooks · doi:10.17118/11143/16021 · Cited by 1
Jeka, M., Jeka, D., Daniszewski, E., & Mojs, E. H. (2023) · Rheumatology Forum · doi:10.5603/rf.a2023.0011 · Cited by 1
Behavioral Medicine Review: The Dialectic of Tradition and Progress in Osteoarthritis Management
Terre, L. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607301806 · Cited by 1
Veterinary Adverse Reactions and Crisis Management
Woodward, K. (2009) · Wiley eBooks · doi:10.1002/9781444322958.ch29 · Cited by 1
Data Mining and Other Informatics Approaches to Pharmacoepidemiology
Bate, A., Trifirò, G., Avillach, P., & Evans, S. J. W. (2019) · Pharmacoepidemiology · doi:10.1002/9781119413431.ch27 · Cited by 1
Phase IV: Postmarketing Trials
Wegscheider, K. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse213
Vioxx®, lessen over veiligheid en omzet
van der Does, E. (2005) · Medisch-Farmaceutische Mededelingen · doi:10.1007/bf03058665
Proposed Legislation May Compromise Incentive to Present Unbiased Presentation of Research Data
Tereskerz, P. M., & Mills, A. (2012) · Accountability in Research · doi:10.1080/08989621.2012.638599
Medication safety: opening up the black box
Mintzes, B. J. (2013) · BMJ Quality & Safety · doi:10.1136/bmjqs-2013-002238
A BITTER PILL TO SWALLOW: CANADIAN DRUG REGULATION
Taylor, M. D. (2010) · bepress Legal Repository · Cited by 1
Reviewbias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010)
Vormt chronisch NSAID-gebruik een indicatie voor permanent gebruik van protonpompremmers?
Dijkmans, B. A. C. (2006) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8808-0_1632
Shimura, H., Masuda, S., & Kimura, H. (2011) · Iryo To Shakai · doi:10.4091/iken.21.17
Marangos, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812796-4.00006-4
Ponce, M. F. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3119644
(2019) · Éditions de l'Université de Sherbrooke eBooks · doi:10.17118/11143/16035
Discourse, materiality and power: Dietary supplements and their users
Bidwell, S. (2020) · Otago University Research Archive (University of Otago) · Cited by 1
Conflict Is in the Eye of the Beholder
Toledo, P., & Banayan, J. M. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005222
Current awareness: Pharmacoepidemiology and drug safety
(2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1034
Regulatory Reform – Changes Needed
(2008) · Springer eBooks · doi:10.1007/978-1-4020-8907-7_25
Offor, I., Abubakar, H. F., & Joda, A. E. (2022) · American Journal of Pharmacotherapy and Pharmaceutical Sciences · doi:10.25259/ajpps_8_2022
How the Hope of Profit Engenders Economic Behaviors
Tang, J. (2025) · Finance & Economics · doi:10.61173/zb8fsr78
Industry Influence on Healthcare Provider Behaviors
Murayama, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-07649-6_3
The evolution of ethical and legal regulations of drug research
Polak, A., Zagaja, A., & Drozd, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104653 · Cited by 1
Clinical trials in rheumatology: patient motivations and concerns as key determinants of recruitment
Jeka, M. (2026) · Reumatologia/Rheumatology · doi:10.5114/reum/218877
Melancon, S. I. (2014) · UA Campus Repository (The University of Arizona)
Metadata
- Authors
- Waxman, H. A.
- Corresponding author
- Waxman, Henry A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-23
- Volume
- 352
- Issue
- 25
- Pages
- 2576-2578
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994883059
- Cited by
- 99
- References
- 2
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 1 · 2013: 3 · 2012: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- rofecoxib, drug safety, pharmaceutical marketing, pharmaceutical industry, drug approval, adverse drug reactions, congressional hearings
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Drug Evaluation, Drug Industry, Gastrointestinal Diseases, Humans, Lactones, Myocardial Infarction, Naproxen, Sulfones, United States, Scientific Misconduct, Cyclooxygenase Inhibitors, Marketing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.